Jeng-Shin Lee, MD, PhD
Dr. Jeng-Shin Lee is the Deputy Director of Harvard Gene Therapy Initiative, an organization founded in 1998 within Harvard Medical School with the objective of promoting the use of gene transfer technology in both research and therapeutic applications. Over the last ten years, his group has been primarily responsible for the development of three cell based products intended for cancer immunotherapy, the development of both research and clinical grade production of adeno-associated viral vectors targeting neuromuscular systems, as well as newer generation lentiviral vector systems. The work has supported four approved investigational new drug (IND) applications in the United States and Europe, in collaboration with physician scientists at Dana Farber Cancer Institute and elsewhere.
Before joining Harvard Gene Therapy Initiative in 1999, Dr. Lee received post-doctoral training at Whitehead Institute, MIT, and Children’s Hospital, Boston. Prior to that, he received his PhD in Virology from Harvard University in 1995 and MD from National Taiwan University in 1990.
Dr. Lee has served as a board director of Monte Jade New England since 2001, and was elected as the Chairman in 2004/2005.